BillionToOne, Inc. Class A Common Stock
$110.67
$7.06 (+6.81%)
$104.48Day Range$111.00
Key Statistics
Market Cap
$5.22B
Shares Outstanding
47.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 6, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$105.36
Day High
$111.00
Day Low
$104.48
Volume
547.3K
VWAP
$109.44
Prev Close
$103.61
Transactions
--
Acc. Volume
--
About BillionToOne, Inc. Class A Common Stock
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
SERVICES-MEDICAL LABORATORIESSIC 8071713 employees1035 O'BRIEN DRIVE, MENLO PARK, CA650-460-2551IPO Nov 6, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002070849
- Composite FIGI
- BBG00NR7JXT0
- Share Class FIGI
- BBG00NR7JXV7
- Ticker Root
- BLLN
- SIC Code
- 8071
About BillionToOne, Inc. Class A Common Stock (BLLN) Stock
BillionToOne, Inc. Class A Common Stock (BLLN) closed the 2026-09-17 session at $110.67, up 6.81% versus the previous close (+7.06). The stock opened at $105.36 and traded between $104.48 and $111.00 during that session. Session trading volume was 547K shares. The volume-weighted average price (VWAP) is $109.44.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
BillionToOne, Inc. Class A Common Stock has a market capitalization of $5.22 billion. The company operates in the SERVICES-MEDICAL LABORATORIES industry classification. BLLN is listed on the XNAS exchange. The company employs approximately 713 people. BillionToOne, Inc. Class A Common Stock is headquartered in MENLO PARK, CA. The recorded listing date is 2025-11-06.
On this page you can find market BLLN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-MEDICAL LABORATORIES sector.